Price discovery
The most important price discovery in equity markets does not happen on the exchange. It happens in the conversations between desks — the bilateral negotiation that never touches the tape. Retail investors see the last sale. Institutional participants see the bid-ask dynamic, the size behind it, and the willingness of the contra side to move. Those are three entirely different pictures of the same security.
What we do on the OTC desk is essentially translate between those pictures. A portfolio manager calls with a block — say, two million shares of a mid-cap name with average daily volume of four hundred thousand. The exchange cannot absorb that without moving the market against the seller. So the block comes to us. We find the other side, we negotiate the spread, and we cross it away from the tape. The PM gets a clean fill. The market never sees the order. That is the service.
Common misreadings
Retail investors consistently misread spread dynamics in thinly traded names. They look at the quoted spread — say, five cents on a ten-dollar stock — and think that is the cost of the trade. It is not. The quoted spread is the cost of a small trade. The effective spread on a meaningful position is a function of depth, not just the inside market.
When a retail investor buys five hundred shares, they pay the ask. When an institution buys five hundred thousand shares, they move the ask. The market impact of that order is the real cost, and it is invisible in the quoted spread. This is why institutional desks spend so much time on execution quality — the difference between a good fill and a bad fill on a large position is often larger than the alpha the PM generated in the first place.
The second misreading is around dark pools. Retail participants tend to view dark pool activity as inherently suspicious — as if institutions are hiding something. In reality, dark pools exist precisely to protect large orders from predatory algorithms that would front-run them on lit exchanges. The institution is not hiding from the market. It is protecting its clients from a specific class of market participant that profits from information asymmetry.
The edge in biotech trading is not technical analysis. It is understanding what the data actually means before the market consensus forms.
Pharma & biotech
The intersection of pharmaceutical capital markets and OTC equity trading is more significant than most people appreciate. Biotech names — particularly pre-revenue, clinical-stage companies — trade with characteristics that are closer to options than to equities. The binary nature of a Phase III readout means that the stock can move fifty percent in either direction on a single data release.
When we are making markets in those names, we are essentially pricing optionality. The spread we quote reflects not just the current bid-ask but our view on the distribution of outcomes around the next catalyst. A company with a PDUFA date in six weeks trades differently than the same company the week after approval. The desk has to understand the clinical landscape, the regulatory pathway, and the competitive dynamics — not just the chart.
This is why the best pharmaceutical equity traders I have worked with all have some scientific background or have spent time with the medical affairs teams at the companies they cover. The edge in biotech trading is not technical analysis. It is understanding what the data actually means before the market consensus forms.
Signals & indicators
The signals we watch are not the ones that appear in retail trading guides. We watch the options market — specifically the skew and the term structure of implied volatility. When the skew steepens dramatically on a name, it tells us that sophisticated participants are paying up for downside protection. That is information. It does not tell us the stock is going down, but it tells us that someone with a large position is worried enough to pay for insurance.
We also watch the borrow market. When the cost to borrow a name spikes, it means short sellers are competing for a limited supply of shares to sell. That competition is itself a signal — it tells us that the short thesis is crowded, which means a short squeeze is a real risk. A crowded short in a name with a near-term catalyst is one of the most dangerous setups in equity markets.